News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Argenica Therapeutics.
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX gets another crack at record high, McGrath to be delisted after buyout
Health & Biotech
ASX Health Stocks: Argenica flies over 15pc after FDA grants Rare Pediatric Disease Designation
Health & Biotech
ASX Health Stocks: CSL’s Phase 3 AEGIS-II trial disappoints, fails to meet primary efficacy endpoint
News
In Case You Missed It: Heavy mineral sands, a biotech takeover and some gold
Health & Biotech
ASX Health Stocks: Mach7 signs $10m deal; Volpara agrees to $300m takeover from South Korean outfit
Health & Biotech
Argenica on track to commence patient dosing for Phase 2 stroke clinical trial in Q1
News
Market Highlights: Fed message sparks rallies in stocks, gold, cryptos; and 5 ASX small caps to watch today
News
In Case You Missed It: Copper hits and gold production on the horizon
Stockhead TV
Long Shortz with Argenica Therapeutics: A new phase for the brain-treating ARG-007
News
In Case You Missed It: Lithium and gold and data centres lead the way
Health & Biotech
US FDA grants Argenica Orphan Drug designation to treat ‘devastating condition’ in newborns
News
In Case You Missed It: Lithium exploration licences and Medicare reimbursement for US medtech play
Health & Biotech
Argenica gets cash boost ahead of critical Phase 2 clinical trial
News
In Case You Missed It: A coal takeover attempt and gold plays round out the day
Health & Biotech
Data shows Argenica’s drug inhibits another main cause of Alzheimer’s disease
Health & Biotech
ASX Health Stocks: Neuren up 17pc on DAYBUE sales, Argenica +40pc on Alzheimer’s data
News
